JP6960856B2 - ヒト化インフルエンザモノクローナル抗体およびその使用方法 - Google Patents

ヒト化インフルエンザモノクローナル抗体およびその使用方法 Download PDF

Info

Publication number
JP6960856B2
JP6960856B2 JP2017553107A JP2017553107A JP6960856B2 JP 6960856 B2 JP6960856 B2 JP 6960856B2 JP 2017553107 A JP2017553107 A JP 2017553107A JP 2017553107 A JP2017553107 A JP 2017553107A JP 6960856 B2 JP6960856 B2 JP 6960856B2
Authority
JP
Japan
Prior art keywords
antibody
acid sequence
seq
binding
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017553107A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018518940A (ja
JP2018518940A5 (enExample
Inventor
ウェイン エイ． マラスコ
Original Assignee
デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド filed Critical デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド
Publication of JP2018518940A publication Critical patent/JP2018518940A/ja
Publication of JP2018518940A5 publication Critical patent/JP2018518940A5/ja
Priority to JP2021083700A priority Critical patent/JP2021121204A/ja
Application granted granted Critical
Publication of JP6960856B2 publication Critical patent/JP6960856B2/ja
Priority to JP2023116535A priority patent/JP2023130499A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • C07K16/108—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2017553107A 2015-04-08 2016-04-08 ヒト化インフルエンザモノクローナル抗体およびその使用方法 Active JP6960856B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021083700A JP2021121204A (ja) 2015-04-08 2021-05-18 ヒト化インフルエンザモノクローナル抗体およびその使用方法
JP2023116535A JP2023130499A (ja) 2015-04-08 2023-07-18 ヒト化インフルエンザモノクローナル抗体およびその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562144729P 2015-04-08 2015-04-08
US62/144,729 2015-04-08
PCT/US2016/026800 WO2016164835A1 (en) 2015-04-08 2016-04-08 Humanized influenza monoclonal antibodies and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021083700A Division JP2021121204A (ja) 2015-04-08 2021-05-18 ヒト化インフルエンザモノクローナル抗体およびその使用方法

Publications (3)

Publication Number Publication Date
JP2018518940A JP2018518940A (ja) 2018-07-19
JP2018518940A5 JP2018518940A5 (enExample) 2019-05-16
JP6960856B2 true JP6960856B2 (ja) 2021-11-05

Family

ID=55754481

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017553107A Active JP6960856B2 (ja) 2015-04-08 2016-04-08 ヒト化インフルエンザモノクローナル抗体およびその使用方法
JP2021083700A Pending JP2021121204A (ja) 2015-04-08 2021-05-18 ヒト化インフルエンザモノクローナル抗体およびその使用方法
JP2023116535A Withdrawn JP2023130499A (ja) 2015-04-08 2023-07-18 ヒト化インフルエンザモノクローナル抗体およびその使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021083700A Pending JP2021121204A (ja) 2015-04-08 2021-05-18 ヒト化インフルエンザモノクローナル抗体およびその使用方法
JP2023116535A Withdrawn JP2023130499A (ja) 2015-04-08 2023-07-18 ヒト化インフルエンザモノクローナル抗体およびその使用方法

Country Status (9)

Country Link
US (2) US11135282B2 (enExample)
EP (1) EP3280730B1 (enExample)
JP (3) JP6960856B2 (enExample)
KR (1) KR102668588B1 (enExample)
CN (1) CN107750253B (enExample)
AU (2) AU2016246065B2 (enExample)
CA (1) CA2981969C (enExample)
IL (2) IL254951B (enExample)
WO (1) WO2016164835A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
CA2940196C (en) * 2014-03-19 2023-03-07 Wayne Marasco Immunogenetic restriction on elicitation of antibodies
EP3419663A1 (en) 2016-02-24 2019-01-02 Visterra, Inc. Formulations of antibody molecules to influenza virus
CA3038504A1 (en) 2016-10-14 2018-04-19 Dana-Farber Cancer Institute, Inc. Modular tetrameric bispecific antibody platform
CN111670195B (zh) * 2018-01-26 2024-08-13 瑞泽恩制药公司 针对流感血凝素的人抗体
WO2019178356A1 (en) 2018-03-14 2019-09-19 Dana-Farber Cancer Institute, Inc. Engineered cells, t cell immune modulating antibodies and methods for using the same
EP3837546A1 (en) 2018-08-13 2021-06-23 Regeneron Pharmaceuticals, Inc. Therapeutic protein selection in simulated in vivo conditions
CN109448781B (zh) * 2018-11-06 2021-09-14 云南大学 一种流感病毒抗原变化的预测方法
CN111423507B (zh) * 2019-01-10 2022-04-15 中国科学院分子细胞科学卓越创新中心 广谱性中和流感病毒的全人抗体
AU2020248404A1 (en) 2019-03-25 2021-09-30 Visterra, Inc. Compositions and methods for treating and preventing influenza
EP4073107A1 (en) * 2019-12-11 2022-10-19 Visterra, Inc. Compositions and methods for treating and preventing influenza
JP2024542158A (ja) 2021-11-05 2024-11-13 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド ヒト広域交差反応性インフルエンザモノクローナル抗体及びその使用方法
CN114366809B (zh) * 2022-01-12 2024-07-23 广州瑞贝斯药业有限公司 一种铝纳米晶递送系统及其结合疫苗抗原分子自组装颗粒佐剂疫苗

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
DE3788058T2 (de) 1986-08-28 1994-04-21 Teijin Ltd Zelltoxischer antikörperkomplex und verfahren zu seiner herstellung.
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
CA2062795A1 (en) 1989-06-29 1990-12-30 Michael W. Fanger Bispecific reagents for aids therapy
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
EP0547065B1 (en) 1990-06-29 2001-08-29 Large Scale Biology Corporation Melanin production by transformed microorganisms
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DK0546073T3 (da) 1990-08-29 1998-02-02 Genpharm Int Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
US5233409A (en) 1992-02-25 1993-08-03 Schwab Karl W Color analysis of organic constituents in sedimentary rocks for thermal maturity
EP0652950B1 (en) 1992-07-24 2007-12-19 Amgen Fremont Inc. Generation of xenogeneic antibodies
MD1367C2 (ro) 1992-11-13 2000-11-30 Idec Pharmaceuticals Corporation Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
CA2183667A1 (en) 1994-02-22 1995-08-24 Wayne A. Marasco Nucleic acid delivery system, method of synthesis and uses thereof
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
MY183517A (en) 2009-05-11 2021-02-24 Janssen Vaccines & Prevention Bv Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof
WO2011117848A1 (en) * 2010-03-26 2011-09-29 Pomona Ricerca S.R.L. Full-length immunoglobulins of the igg isotvpe capable of recognizing a heterosubtvpe neutralizing epitope on the hemagglutinin stem region and their use as anti-influenza medicament
US9534042B2 (en) * 2010-09-03 2017-01-03 Fujita Health University Influenza virus-neutralizing antibody and screening method therefor
ES2608321T3 (es) 2011-07-14 2017-04-07 Janssen Vaccines & Prevention B.V. Moléculas de unión humanas capaces de neutralizar virus de la gripe A del grupo filogenético 1 y del grupo filogenético 2 y virus de la gripe B
PL2734545T3 (pl) * 2011-07-18 2019-09-30 Institute For Research In Biomedicine Neutralizujące przeciwciała przeciwko wirusowi grypy A i ich zastosowania
KR101514682B1 (ko) * 2011-09-30 2015-04-23 (주)셀트리온 인간 ｂ 세포에서 생산된 인플루엔자 ａ 바이러스 중화 활성을 가지는 결합 분자
US9969794B2 (en) * 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
AU2013345072B2 (en) * 2012-11-13 2017-12-07 Genentech, Inc. Anti-hemagglutinin antibodies and methods of use
US9111624B2 (en) 2013-03-22 2015-08-18 Katsuyuki Fujita Semiconductor memory device

Also Published As

Publication number Publication date
US20220054624A1 (en) 2022-02-24
JP2018518940A (ja) 2018-07-19
AU2016246065A1 (en) 2017-10-26
US20180099040A1 (en) 2018-04-12
CA2981969A1 (en) 2016-10-13
JP2021121204A (ja) 2021-08-26
EP3280730A1 (en) 2018-02-14
AU2021225240A1 (en) 2021-09-30
CA2981969C (en) 2023-12-05
CN107750253B (zh) 2022-10-04
WO2016164835A1 (en) 2016-10-13
EP3280730C0 (en) 2024-01-03
IL254951B (en) 2021-09-30
IL286208A (en) 2021-10-31
EP3280730B1 (en) 2024-01-03
KR20170133507A (ko) 2017-12-05
CN107750253A (zh) 2018-03-02
US12076390B2 (en) 2024-09-03
AU2016246065B2 (en) 2021-06-03
IL254951A0 (en) 2017-12-31
KR102668588B1 (ko) 2024-05-22
JP2023130499A (ja) 2023-09-20
US11135282B2 (en) 2021-10-05

Similar Documents

Publication Publication Date Title
JP6960856B2 (ja) ヒト化インフルエンザモノクローナル抗体およびその使用方法
AU2008338691B2 (en) Antibodies against influenza virus and methods of use thereof
JP2024542158A (ja) ヒト広域交差反応性インフルエンザモノクローナル抗体及びその使用方法
AU2019204310B2 (en) Antibodies against influenza virus and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171108

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190404

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190404

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200501

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200805

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210518

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210518

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20210526

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210624

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20210624

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20210628

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210902

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211004

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211012

R150 Certificate of patent or registration of utility model

Ref document number: 6960856

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250